Table 7.
Startup Activities for which Top Startup Participants Are Engaged Relative to Each Emerging Research Topic.
| Startup Participant | Role | Startup Company | Company Overview Brief Description |
Most Recent Financing (MM) |
|---|---|---|---|---|
| Exosome | ||||
| Zhang, Bin | VP | Cisen Pharmaceutical Co. Ltd. | Manufacturer of chemical pharmaceutical agents and related products such as non- polyvinyl chloride (PVC) soft bag infusions, plastic bottle infusions, lyophilized powder injections, tablets, ointments, eye drops, and capsules | 09/29/2017 IPO 1166.00RMB (Chinese Yuan) |
| Chen, Wei | Board Member, Outsider | Immunophotonics, Inc. | Developer of a cancer treatment | 09/04/2014 VC 1st 2.49 USD |
| Xu, Bin | EVP | Grandhope Biotech Co. Ltd. | Provider of medical materials and devices for the treatment of damaged tissue and organs | 07/06/2011 IPO 278.4 RMB (Chinese Yuan) |
| Johansson, Henrik J. | Unknown Executive | Halo Genomics AB | Developer of targeted re-sequencing technology for DNA sequencing | Acquired by Agilent |
| Microbiome | ||||
| Xavier, Ramnik J. | Cofounder | Jnana Therapeutics | Developer of drugsthat target cellular proteins | 12/14/2017 VC 1st 50.00 USD |
| de Vos, Willem M. | Chairman, Scientific Advisory Board | MicroDish BV | Developer of micro-engineered culture chips and nanoscale reagents aiming to improve microbial culture | 03/31/2011 VC 1st N.A. |
| Mazmanian, Sarkis | Director | AxialBiotherapeutics Inc. | Developer of biotherapeuticsthat target neurological diseases and disorders | 06/22/2017 VC 1st 19.20 USD |
| CRISPR | ||||
| Zhang, Feng | Cofounder | Editas Medicine | Developer of human therapeutics based on genome editing technologies | 02/03/2016 IPO 94.40 USD |
| Doudna, Jennifer A. | Cofounder | Editas Medicine | Same as above | Same as above |
| Cofounder | Intellia Therapeutics, Inc. | Provider of CRISPR-Cas9 focused biotechnology | 05/06/2016 IPO 108.00USD |
|
| Joung, J. Keith | Cofounder | Editas Medicine | Developer of human therapeutics based on genome editing technologies | Same as above |
| Cas9 | ||||
| Zhang, Feng | Cofounder | Editas Medicine | Developer of human therapeutics based on genome editing technologies | Same as above |
| Doudna, Jennifer A. | Cofounder | Editas Medicine | Same as above | Same as above |
| Cofounder | Intellia Therapeutics, Inc. | Provider of CRISPR-Cas9 focused biotechnology | Same as above | |
| Joung, J. Keith | Cofounder | Editas Medicine | Developer of human therapeutics based on genome editing technologies | Same as above |
| CAR-T | ||||
| June, Carl H. | Cofounder | Tmunity Therapeutics | Developer of T-cell immunotherapies | 01/23/2018 VC 2nd 100.00USD |
| Sadelain, Michel | Cofounder | Juno Therapeutics Inc. | Developer of medicines to treat cancer | 12/19/2014 IPO 264.55USD |
| Riviere, Isabelle | Cofounder | Juno Therapeutics Inc. | Same as above | Same as above |
| Zika | ||||
| Osorio, Jorge E. | Chief Scientific Officer | Inviragen Inc. | Developer of vaccines to protect against infectious diseases | 06/07/2013 Acquired by Takeda |
| Schinazi, Raymond F. | Founder | Pharmasset Inc. | Developer of drugs to treat viral infections | 04/27/2007 IPO 45.00 USD |
| Board Member, Outsider | Gliknik Inc. | Developer of cancer, autoimmune, and inflammatory disease therapies | 09/30/2013 Corporate Partnership 25.00 |
|
| Board Member, Outsider | ReViral Ltd. | Developer of antiviral drugs focused on diseases caused by the respiratory syncytial virus (RSV) | 09/08/2015 VC 1st 21.00 USD |
|